A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials
- 22 April 2018
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 37 (15) , 2307-2320
Abstract
In randomized clinical trials where time‐to‐event is the primary outcome, almost routinely, the logrank test is prespecified as the primary test and the hazard ratio is used to quantify treatment effect. If the ratio of 2 hazard functions is not constant, the logrank test is not optimal and the interpretation of hazard ratio is not obvious. When such a nonproportional hazards case is expected at the design stage, the conventional practice is to prespecify another member of weighted logrank tests, eg, Peto‐Prentice‐Wilcoxon test. Alternatively, one may specify a robust test as the primary test, which can capture various patterns of difference between 2 event time distributions. However, most of those tests do not have companion procedures to quantify the treatment difference, and investigators have fallen back on reporting treatment effect estimates not associated with the primary test. Such incoherence in the “test/estimation” procedure may potentially mislead clinicians/patients who have to balance risk‐benefit for treatment decision. To address this, we propose a flexible and coherent test/estimation procedure based on restricted mean survival time, where the truncation time τ is selected data dependently. The proposed procedure is composed of a prespecified test and an estimation of corresponding robust and interpretable quantitative treatment effect. The utility of the new procedure is demonstrated by numerical studies based on 2 randomized cancer clinical trials; the test is dramatically more powerful than the logrank, Wilcoxon tests, and the restricted mean survival time–based test with a fixed τ, for the patterns of difference seen in these cancer clinical trials.Keywords
This publication has 36 references indexed in Scilit:
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- Improved Logrank‐Type Tests for Survival Data Using Adaptive WeightsBiometrics, 2010
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2008
- The Versatility of Function-Indexed Weighted Log-Rank StatisticsJournal of the American Statistical Association, 1999
- Some Versatile Tests Based on the Simultaneous Use of Weighted Log-Rank Statistics1996
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993
- Weighted log rank type statistics for comparing survival curves when there is a time lag in the effectiveness of treatmentBiometrika, 1990
- The Use of Maximin Efficiency Robust Tests in Combining Contingency Tables and Survival AnalysisJournal of the American Statistical Association, 1985